Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

NewLink Genetics Corp

+ Add to Watchlist


56.4000 USD 4.1400 7.92%

As of 17:20:00 ET on 03/30/2015.

Snapshot for NewLink Genetics Corp (NLNK)

Open: 52.8000 Day's Range: 52.5400 - 56.6500 Volume: 668,841
Previous Close: 52.2600 52wk Range: 17.3201 - 57.4700 1-Yr Rtn: +118.35%

Stock Chart for NLNK

No chart data available.
  • NLNK:US 56.4400
  • 1D
  • 1M
  • 1Y
Interactive NLNK Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for NLNK

Current P/E Ratio (ttm) 17.6803
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) 3.1900
Est. EPS (USD) (12/2015) -1.8280
Est. PEG Ratio -
Market Cap (M USD) 1,606.19
Shares Outstanding (M) 28.48
30 Day Average Volume 572,944
Price/Book (mrq) 7.7443
Price/Sale (ttm) 9.1351
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/06/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for NLNK

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for NLNK

NewLink Genetics Corporation is a biopharmaceutical company. The Company develops and commercializes biologic and small-molecule immunotherapy products intended to treat a wide range of cancers. NewLink's products are designed to harness components of the patient's immune system to fight cancer either alone or in combination with other treatment regimens.

Charles J Link JrChairman/CEO/Chief Scientific OfcrNicholas N VahanianPresident/Chief Medical Ofcr
John B Henneman III "Jack"Exec VP/CFO/SecretaryBrian WileyVP:Business Development
More Company Profile & Key Executives for NLNK

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil